Sagimet Biosciences SGMT 深 滬
等待開盤 01-29 09:30:00 美东时间
5.855
-0.235
-3.86%
華盛通- 最 高6.15
- 今 開6.11
- 成交量 38.80万股
- 最 低 5.85
- 昨 收 6.09
- 總市值 1.90亿
- 52周最高 11.41
- 市盈率 靜 --
- 換手率 1.19%
- 52周最低 1.73
- 委 比 73.92%
- 總股本 3252.16万
- 歷史最高 20.71
- 量 比 0.89
- 振 幅 4.93%
- 歷史最低 1.73
- 每 手 1
- 風險率 2.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
今天 11:06
Barclays Initiates Coverage On Sagimet Biosciences with Equal-Weight Rating, Announces Price Target of $8
Barclays analyst Eliana Merle initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Equal-Weight rating and announces Price Target of $8.
01-28 22:50
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet Biosciences will present a poster at the 10th Annual MASH-TAG Conference in Park City, Utah, on January 10, 2026. The presentation will highlight the anti-fibrotic effects of denifanstat, a FASN inhibitor, in F3 and qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 trial. Denifanstat showed significant improvement in fibrosis and biomarkers in these patients. MASH is a severe liver disease affecting over 265 million people, wi...
01-08 12:00
Sagimet Reports MASH Combo Data, Eyes Phase 2 for Liver Treatment
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive results in the Phase 1
2025-12-18 20:03
Sagimet Biosciences enters global license agreement with TAPI
Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an update. Sagimet ...
2025-12-17 20:28
Sagimet Biosciences Announced A License Agreement With A Subsidiary Of Teva Pharmaceutical
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports
2025-12-17 20:06
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
Sagimet Biosciences announced that China's NMPA has accepted the New Drug Application (NDA) for denifanstat, developed by Ascletis Pharma, to treat moderate to severe acne. Sagimet licensed denifanstat to Ascletis for China, while developing it for metabolic dysfunction-associated steatohepatitis (MASH) outside China. Denifanstat, as ASC40 in China, successfully met all endpoints in Phase 3 trials for acne. Sagimet is also exploring denifanstat i...
2025-12-10 12:03
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences Inc. has granted 42,800 stock options to three new employees under Nasdaq Rule 5635(c)(4). The options, with an exercise price based on the December 9, 2025, closing price, vest over four years and have a ten-year term. Sagimet, a clinical-stage biopharmaceutical company, focuses on developing FASN inhibitors targeting metabolic and fibrotic pathways. Its lead product, denifanstat, met Phase 2b and Phase 3 endpoints in metabol...
2025-12-09 21:05
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences announced that its management will participate in the 8th Annual Evercore ISI Healthcare Conference on December 2, 2025, with a fireside chat at 12:55pm ET. A webcast of the event will be available on Sagimet’s website, with an archived replay for 90 days. Sagimet focuses on developing novel FASN inhibitors targeting metabolic and fibrotic pathways, with its lead product denifanstat showing positive results in clinical trials.
2025-11-20 12:00
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
